Fig. 3
Down-regulation of hsa-miR-3178 inhibited proliferation of PANC-1-GEM cells and increased sensitivity of cells to gemcitabine. A CCK-8 assay on cell viability of PANC-1-GEM cells transfected with Mock, INC, and hsa-miR-3178 inhibitor and treated with gemcitabine for calculating IC50. B The CCK-8 growth curves of indicated cells upon treatment with gemcitabine (150 μmol/L). (C) The representative fluorescent micrograph and quantification of EdU staining on indicated cells upon treatment with gemcitabine (150 μmol/L). D Flow cytometry on cell apoptosis in indicated cells exposed to gemcitabine (150 μmol/L) for 72 h. E Tumor xenograft images from mice treated with gemcitabine (5 mg/kg, IP, q3d). F Tumor weights showed the effects of hsa-miR-3178 inhibitor on the indicated groups. G Tumor volumes measured on the indicated times. Data are expressed as mean ± SD from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. PANC-1-GEM: gemcitabine resistant subline. IC50: half-inhibitory concentration; Mock: untreated cells; INC: Inhibitor negative control; PI: Propidium Iodide; FITC: Fluorescein Isothiocyanate; IP: intraperitoneal injection